Our findings demonstrate a new mechanism by which JMJD6 coordinates metabolic programs and alternative pre-mRNA splicing, providing a rationale to target JMJD6 as a therapeutic target for MYC-driven cancers. The gene discussed is JMJD6; the disease is cancer.